Novel Therapy for Diabetes, Dyslipidemia and Obesity


Description

Researchers at the University of Alberta have discovered a potential therapy to prevent dyslipidemia, obesity, diabetes and atherosclerosis. The study shows that depletion of an enzyme inhibits phosphatidylcholine synthesis in mice which results in decreased levels of blood cholesterol and triglycerides. Associated mechanisms, which include large increases in the hormone GLP-1 following a meal, protect the mice from high-fat-diet-induced obesity.

Dyslipidemia is characterized by abnormal levels of lipid in the bloodstream. The primary cause of dyslipidemia is genetic disorders that result in either defective clearance of cholesterol or triglycerides or its overproduction. Diabetes is a secondary cause of dyslipidemia which is associated with a high risk of developing cardiovascular disease. Research has shown that a healthy diet and exercise helps in the management of dyslipidemia. However, treatment to reduce the level of cholesterol and triglycerides remains essential. Therefore, it is essential to develop new lines of treatment and prevent disease progression in patients suffering from dyslipidemia.

Advantages

  • The novel discovery can potentially be used to treat patients with dyslipidemia and obesity.
  • Animal model available

Potential Markets

We are seeking pharmaceutical partners for collaborative development and licensing.

Protection Status

Patent Pending

Product Number

2016058

Contact Information

Megha Bajaj
Technology Management Group
TEC Edmonton – University of Alberta
Phone: 780-492-7739
​Email: megha.bajaj@tecedmonton.com